457653-91-7

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 80885-30-9 (E)-4-(benzyloxy)-2-buten-1-ol 
• 91142-50-6 4-benzyloxy-2-butyn-1-ol 
• 4039-82-1 Benzyl propargyl ether 
• 100-39-0 benzyl bromide 

Downstream Products

• 439112-50-2 (2S,3R)-3-(benzyloxymethyl)-2-(4-methoxyphenyl)pent-4-enoic acid (S)-2,2-dimethyl-1-(methylcarbamoyl)propylamide 
• 439112-51-3 (2R,3S)-2-(benzyloxymethyl)-N-[(S)-2,2-dimethyl-1-(methylcarbamoyl)propyl]-3-(4-methoxyphenyl)succinamic acid 
• 205807-59-6 TNF₄₈₄ 
• 439112-49-9 (2S,3R)-3-(benzyloxymethyl)-2-(4-methoxyphenyl)pent-4-enoic acid 

Relevant academic research and scientific papers

HYDROXAMIC ACID DERIVATIVES

Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimm

Process development of a dual MMP/TNF inhibitor (SDZ 242-484)

The compound (2R,3S)-N-4-((S)-2,2-Dimethyl-1-methylcarbamoyl-propyl)-N-1-hydroxy-2- hydroxymethyl-3-(4-methoxy-phenyl)-succinamide (1; SDZ 242-484) shows antiinflammatory effects due to inhibition of matrix metalloproteases (MMP) and tumor necrosis factor